Introduction
P ositron emission tomography (PET) is routinely used for cancer diagnosis, staging, and therapy monitoring. In many cancers, tumor cell proliferation is an important prognostic factor and is a key factor to monitoring efficacy of anticancer therapy. Therefore, radiopharmaceuticals directly related to cell proliferation, such as 3′-deoxy-3′-[ 18 [2] . Prior studies have established that [ 18 F]FLT uptake correlates with Ki-67 immunostaining proliferation assay, in breast cancer [3] , lung cancer [4] , and leukemia [5] , and with S phase fraction in lung tumors as measured by flow cytometry [6] . Tumor imaging with [ 18 F]FLT PET has been shown to be generally specific in cancer diagnosis [7] . However, nonspecific incorporation can be observed in proliferating macrophages in inflammatory lesions [8] . It also appears to predict outcome after chemotherapy [9] , radiotherapy [10] as well as progression and overall survival of patients with brain tumors [11] . Moreover, in breast cancer [12] and in high-grade non-Hodgkin's lymphoma [13] , early change in [ 18 F]FLT uptake, immediately after initiation of chemotherapy predicts tumor response to treatment. Thus, [ 18 F]FLT might be an important adjunct in the therapeutic management of cancer patients.
Currently, 2-deoxy-2-[
18 F]fluoro-D-glucose ([ 18 F]FDG) is the most frequently used PET imaging agent for characterization of mass lesions and assessment of response to treatment in a variety of tumors [14] . [ 18 F]FDG, as a glucose analogue, is internalized in cells with enhanced glucose requirement. [ 18 F]FDG incorporation has been found to be correlated with cellular proliferation [15] and, hence, has been considered an indicator of tumor aggressiveness [16] . However, it is a matter of debate whether glucose consumption is a good indicator of tumor aggressiveness. In this study, we addressed part of these limitations by modifying cellular uptake of extracellular thymidine, by interfering with the endogenous DNA synthesis pathway using 5-fluoro-2′-deoxyuridine (FdUrd, floxuridine). We hypothesized that pretreatment with FdUrd might be able to increase tumor uptake of [ 18 F]FLT. Here, FdUrd was used in mice at a nontoxic bolus injection of 2.5 mg/kg, while intravenous (i.v.) bolus treatment in humans is performed with 30 mg/kg [18] . We studied the effect of FdUrd in mice bearing different human tumor xenografts by biodistribution studies and animal PET. [19] . The specific activity was 281±204 GBq/µmol, and the purity was ≥97% for all preparations.
Materials and Methods

Radiopharmaceuticals and Reagents
5-[ 125 I]iodo-2′-deoxyuridine ([ 125 I]IdUrd) of high radiochemical purity was prepared in house using a modified method, originally described by Foulon et al. [20] . FdUrd and 5′-deoxythymidine (dThd) were obtained from Sigma-Aldrich Chemie GmbH (Steinheim, Germany). IdUrd (Sigma-Aldrich Chemie GmbH) was dissolved in distilled water using NaOH alkalinization at minimally required concentration.
Cell Lines and Culture
Two Burkitt lymphomas (Ramos and BL60.2), two human breast adenocarcinomas (MDA-MB231, SKBR127), and two human colon adenocarcinomas (WiDr, LS174T9) were used. All cell lines except BL60.2 (kindly provided by Dr. Stephan Mathas at Delbrück-Center for Molecular Medicine, Berlin, Germany) were obtained from American Type Culture Collection. Cells were cultured at 37°C and 5% CO 2 in RPMI 1640 containing glutamax I (Invitrogen, Grand Island, NY) supplemented with 10% heatinactivated fetal bovine serum (Chemie Brunschwig AG, Basel, Switzerland), penicillin (50 units/mL) and streptomycin (0.05 mg/mL; from Life Technologies Inc., Grand Island, NY).
Since mycoplasma contamination is a source of increased nucleoside turnover that therefore modulates FdUrd efficacy and cellular uptake of thymidine, cells were cultured for 6 months after thawing and tested negative for mycoplasma contaminations (Mycoplasma Detection Kit; F. Hoffmann-La Roche Ltd, Basel, Switzerland).
Mice and Tumor Models
All experiments were performed according to the principles of laboratory animal care and Swiss legislation. The experiments were specifically approved by the official committee on surveillance of animal experiments. Female homozygous athymic Foxn1 nu/nu nude and CB17 SCID mice were obtained from Harlan Laboratories (Boxmeer, Netherlands). Animals were kept under specific pathogen-free conditions, in autoclaved filter-topped cages and bedding in a separate room. Mice had access ad libitum to sterilized food and water.
Suspensions of 5×10 6 cells in 0.07 to 0.1 mL cell culture media were inoculated subcutaneously at inguinal (for biodistribution studies) or thoracic level (for PET studies) in mice of 6 to 8 weeks of age. Experiments were performed after adequate growth of tumors 12 days to 4 weeks after grafting. For experiments including magnetic resonance imaging (MRI), tumors were grafted subcutaneously onto the skull of mice. 18 F]FDG administration, mice were euthanized by CO 2 inhalation and dissected, and organs were weighed and counted as previously described.
Flow
Small-Animal PET
Imaging was performed using an avalanche photodiode microPET scanner (LabPET4; Gamma Medic-Ideas, Sherbrooke, Quebec, Canada). During the entire scanning period, mice were maintained under 1% isoflurane anesthesia in oxygen delivered at 1 L/min using a face mask and under monitoring of temperature and breathing rate. For dynamic PET, all animals were pretreated with 2.5 mg/kg FdUrd. List-mode acquisitions of 90 min were initiated 1 min after injection of 24.8±6.0 MBq [
18 F]FLT, via the lateral tail vein. An energy window of 250-650 keV and a coincidence-timing window of 22.2 ns were used. Images were reconstructed by the MLEM iterative method. Images were corrected for nonuniformity of scanner response, dead time count losses, and physical decay to the time of injection.
Images were analyzed with the PMOD 3.0 software (PMOD Technologies, Zurich, Switzerland). For dynamic studies, regions of interest were drawn manually by optical reading of welldelineated normal tissues like heart on early frames and tumors on late frames. These regions of interest were then projected on all dynamic images. Time activity curves were calculated for different areas (tumor, heart, bone, and abdominal activity) and were expressed in kBq/mL.
Magnetic Resonance Imaging
Scans were performed on a 9.4 Tesla Varian (Varian Medical Systems, Palo Alto, CA) 21-cm horizontal-bore scanner with a 12-cm 200-mT/m gradient insert (Magnex Scientific, Oxford, UK) [22] . Respiration was monitored during the measurement, and body temperature was maintained at 37°C. MRI was performed for head implanted tumors, using tight immobilization of the animal head with bilateral ear pins and maxillary fixation. Multislice fast-spin-echo T2-weighted images (using a repetition time of 4 s and an echo time of 50 ms) were obtained in the coronal and transverse planes using a field of view of 20×20 mm, a slice thickness of 0.7 mm, and a matrix size of 256×256 image voxels.
Tumor Histology and Immunohistochemistry
Tumors were fixed with 4% neutral buffered formalin and embedded in paraffin. For Ki-67 immunostaining, 4-µm-thick sections were cut from paraffin blocks, deparaffinized in xylene, and rehydrated in graded ethanol. Sections were incubated overnight at 4°C with monoclonal mouse antihuman Ki-67 antibody (Dako Schweiz, Baar, Switzerland). For determination of tumor proliferative rate, 1,000 cells per slide were counted at 40× magnification using a standard diagnostic microscope and KI-67-positive cells expressed in percentage of total tumor cells. Standard hematoxylin-eosin (HE) staining was used for evaluation of tumor cell viability and general histological examination. The mitotic index of each tumor was determined by counting the number of mitotic figures on 10 different 40× magnification field of views. Data were expressed as mean ± 1 SD per 10 high power field (HPF).
Statistical Analysis
To evaluate the increase in the mean tumor uptake values during the late period (20 last min) of dynamic PET scanning, two different time frames were compared with each other using the Student's t test. The activity measured over five frames of 1 min each, one starting at 66 min, and the other at 86 min was compared, and P values G 0.05 were considered statistically significant. The Mann-Whitney nonparametric test was used to assess whether tumor uptake of [ 18 F]FLT in FdUrd-pretreated animals was different from control groups, PG0.05 being considered significant and PG0.01 highly significant. Both statistical tests were two sided. Tests were performed using the statistical analysis software SPSS (version 15.0; SPSS, Inc., Chicago, IL).
Results
Timing Dependence of FdUrd Efficacy on Tumor Cells In Vivo
Cell cycle modification induced by FdUrd in vivo was studied by flow cytometry experiments. In BL60.2 and Ramos lymphoma tumors, cell cycle determination was only possible in mice having been pretreated with FdUrd. Without FdUrd pretreatment, IdUrd based S phase staining failed to produce a measurable two-dimensional separation of cells. In BL60.2 cells, the ratio of S phase cells was already high at 1 h after administration of FdUrd (50.6%±7.3%) and was similar at 3 h (50.4%±2.7%). Thereafter, the staining of S phase cells was lost and no longer measurable at 6 h after FdUrd pretreatment. Similarly, in mice bearing Ramos tumors, the number of cells in S phase was very high (61.7%±0.2% of the whole viable cell population) but limited in time, and at 6 h post-FdUrd, the signal vanished ( Fig. 1 ; Table 1 In (Fig 2b) . The absence of increased [
18 F] FLT uptake in spleen and bone marrow after FdUrd pretreatment in these mice might be explained by the fact that they had been treated by whole-body irradiation (2.5 Gy) before tumor transplantation in order to facilitate engraftment of the lymphoma. The biodistribution experiment was performed 11 days after irradiation when bone marrow and spleen cells remained depressed. Biodistribution of [ 18 F]FDG in fasted and anesthetized mice showed that the Ramos tumors incorporated 6.7%±1.2% ID/g 2 h after [
18 F] FDG injection (Fig. 2c) .
Based Fig. 3a ; Table 2 ).
The specificity of the [ 18 F]FLT uptake in FdUrd pretreated mice was confirmed by competitive inhibition with an excess of dThd. In these mice, tumor uptake decreased to 2.0%±0.5% and to 2.4%±0.6% ID/g in MDA-MB231 and SKBR3 xenografts, respectively (Fig. 2a) .
For comparison, [ 18 F]FDG biodistribution was performed 2 h postinjection in fasted and anesthetized mice bearing also MDA-MB231 and SKBR3 breast cancer xenografts. The [
18 F]FDG tumor uptake was 6.6%±0.4% and 4.3%± 1.0% ID/g in MDA-MB231 and SKBR3 tumors, respectively (Fig. 3b) . We had obtained very similar [ 18 F]FDG biodistribution and tumor uptake results, except for muscle, in a pilot study in nonanesthetized, but otherwise identically treated mice (results not shown).
In a separate experiment aiming to further optimize the accumulation of [ 18 F]FLT within tumor cells, the timing of injection was varied in groups of three mice, each bearing two xenografts of the MDA-MB231 breast cancer cell line. In mice without FdUrd pretreatment, the baseline tumor incorporation of [ 18 F]FLT, measured 2 h after radiotracer injection, was rather low with 2.1%±0.2% ID/g. FdUrd pretreatment of mice 10 or 60 min before [ 18 F]FLT injection and dissection at 2 h after radiotracer administration yielded a dramatic increase in tumor uptake, with mean values of 16.6%±2.1% and 15.8%±2.5% ID/g, respectively (Table 3) . When mice, pretreated 1 h before injection of [ 18 F]FLT, were analyzed at 1 h after radiotracer injection, tumor uptake of 15.8%±3.5% ID/g was very similar to the results of dissection after 2 h, but as expected, the activity in normal tissues was markedly higher at 1 h.
In order to reproduce these findings in another tumor type, the effect of FdUrd was measured in mice bearing LS174T and WiDr colon cancer xenografts. In control mice, Table 4 ). In contrast, the background measured in abdomen steadily decreased over the time of observation in all mice. The activity in the heart, important within a few minutes after [ 18 F]FLT injection, decreased rapidly to reach a level comparable with background.
Correlation of PET, MRI, and Histology of a Breast Cancer and Ramos Lymphoma
Imaging on animal-dedicated MRI and PET was performed at 1-day intervals in mice with MDA-MB231 breast cancer (Fig. 6 ) and Ramos tumor xenografts (Fig. 7) . A macroscopic necrotic center of the MDA-MB231 appeared on MRI as a hyperintense structure surrounded by vital tumor. In contrast, the Ramos tumor appeared on MRI to be uniformly viable. The same tumors investigated by PET, using FdUrd pretreatment, showed that the entire Ramos tumor avidly incorporated [
18 F]FLT, whereas in MDA-MB231, a central hypoactive area in PET, corresponding to the necrotic portion in MRI, was surrounded by tumor accumulating [ 18 F]FLT. At the cellular level, histology showed that the Ramos tumor was close to 100% viable and showed a pronounced proliferative activity, as evidenced by immunohistochemistry. In different sections, the mitotic index was 87±22 mitoses /10 HPF, and virtually all tumor cells were MIB-1 positive. In the "viable" rim of MDA-MB231 tumor, 95% of cells were viable and the mitotic index was 37±14 mitoses/ 10 HPF, with a MIB-1 positivity rate of 70% to 80%. In the second breast cancer SKBR3, the "viable" tumor contained between 20% and 35% necrotic cells, while 58±26 mitoses/10 HPF were counted with a MIB-1 positivity rate of 90% to 95%.
Discussion
The tumor uptake of [ 18 [24, 25] and others [26, 27] in vitro and in patients. These observations, considered as a "flare" phenomenon, were to be taken into account when interpreting [
18 F]FLT PET. In our approach, we used a single i.v. injection of a nontherapeutic dose of FdUrd, aimed at improving tumor uptake of [ 18 F]FLT in order to use this procedure in diagnostic PET. We used a dosing and timing of FdUrd pretreatment that had been studied previously in experiments conducted with [ 125 I]IdUrd [21] that is incorporated into DNA.
The endogenous thymidine pool competes with [ 18 F]FLT uptake into proliferating cells. FdUrd directly blocks the endogenous thymidine synthesis without any major impact on other nucleotide pathways. The thymidine synthesis block enhances the salvage pathway and nucleoside transporters promoting enhanced cellular uptake of exogenous thymidine and thymidine analogs. As shown here, this strategy is well applicable to [ 18 F]FLT PET. Since 5-FU is partially converted to FdUrd, this could explain the previously described enhanced uptake of [ 18 F]FLT. Unfortunately, the conversion rate of 5-FU into FdUrd varies greatly among patients and adequate 5-FU dosing would be challenging. Furthermore, adverse effects due to the cytostatic action of 5-FU on RNA synthesis would limit its clinical usefulness in an imaging application [27] .
Timing of PET after [ In normal tissues, however, washout at 3 h was much higher than at 1 h, leading to improved tumor-to-normal tissue ratios.
The observation of prolonged retention of [ 18 F]FLT in lymphoma prompted the evaluation of [
18 F]FLT for cell proliferation PET at 2 h after injection, which would be a compromise between the optimal tumor-to-normal tissue ratio observed at 3 h and the short physical half-live of F-18 of 110 min. Dynamic microPET imaging confirmed that tumor uptake increased up to 1.5 h after [ 18 F]FLT injection in FdUrd pretreated mice. These results suggest that PET performed as early as 1 h after injection would not take optimal advantage of delayed uptake in the tumor cells and tracer elimination from normal tissues.
The results shown here with a low-dose FdUrd pretreatment of animals at 2.5 mg/kg may be clinically relevant as a diagnostic procedure. Indeed, in early patient treatment protocols, a bolus of FdUrd was injected daily i.v. at 30 mg/kg over the first 7 days, followed by further administrations of 15 mg/kg over several additional days [18] . Similarly, high doses of FdUrd have been used more recently for therapy with bolus injections of 3 g daily (∼50 mg/kg) into the peritoneal cavity of patients with peritoneal tumor dissemination [28] . The difference between bolus injection and 24-h perfusion of FdUrd was studied by Sullivan et al. [29] . As compared with massive bolus treatments in patients, administration of a single dose of 2.5 mg/kg used here in mice is underdosed by a factor of 10 or more. Furthermore, in previous studies, we have also shown that a similar efficacy of FdUrd in mice was reached with injections of between 1 and 3 mg/kg [21] . For a first clinical trial, we therefore propose the dose of 1 mg/kg FdUrd, corresponding to a 30-to 50-fold lower dose than reported in daily treatment protocols using bolus injections. While flow cytometry data from tumors grown in vivo suggested that FdUrd had a limited time of efficacy, in the range of about 6 h, this was also confirmed with incorporation studies with [
125 I]IdUrd. Finally, an innocuity test was performed in 10 mice given a single i.v. bolus injection of 100 mg/kg FdUrd. No adverse effect was observed in terms of body weight evolution over 2 months, leukocyte counts at 10 days after injection, nor organ appearance at macroscopic inspection at 60 days (results not shown). Based on these observations, we estimate that the clinical use of FdUrd at a dose of 1 mg/kg in a single bolus i.v. injection can be considered as safe and warrants a first clinical trial. In conclusion, our in vivo data showed a marked tumor uptake increase of [ 18 F]FLT in FdUrd pretreated mice that might be highly clinically relevant and warrants confirmation in patients. Such a study is being planned in patients with aggressive breast cancer. The information gained from the timing and biodistribution experiments has provided important clues for such a clinical trial. We thus propose performing PET imaging 2 h after [
18 F]FLT injection, while pretreatment with FdUrd may be similarly efficient when administered between 10 to 60 min before injection of [ 18 F]FLT.
